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OBJECTIVE — In the Diabetes Therapy Utilization: Researching Changes in A1C, Weight
and Other Factors Through Intervention with Exenatide Once Weekly (DURATION-1) study,
thesafetyandefﬁcacyof30weeksoftreatmentwiththeglucagon-likepeptide-1receptoragonist
exenatide once weekly (exenatide QW; 2 mg) was compared with exenatide BID in 295 patients
with type 2 diabetes. We now report the safety and efﬁcacy of exenatide QW in 1) patients who
continued treatment for an additional 22 weeks (52 weeks total) and 2) patients who switched
from exenatide BID to exenatide QW after 30 weeks.
RESEARCH DESIGN AND METHODS — In this randomized, multicenter, compara-
tor-controlled,open-labeltrial,258patientsenteredthe22-weekopen-endedassessmentphase
(n  128 QW-only; n  130 BID3QW). A1C, fasting plasma glucose (FPG), body weight,
blood pressure, fasting lipids, safety, and tolerability were assessed.
RESULTS — Patients continuing exenatide QW maintained A1C improvements through 52
weeks(leastsquaresmean2.0%[95%CI2.1to1.8%]).Patientsswitchingfromexenatide
BIDtoexenatideQWachievedfurtherA1Cimprovements;bothgroupsexhibitedthesameA1C
reduction and mean A1C (6.6%) at week 52. At week 52, 71 and 54% of all patients achieved
A1C7.0%and6.5%,respectively.Inbothtreatmentarms,FPGwasreducedby40mg/dl,
and body weight was reduced by 4 kg after 52 weeks. Nausea occurred less frequently in this
assessment period and was predominantly mild. No major hypoglycemia was observed.
CONCLUSION — Exenatide QW elicited sustained improvements in glycemic control and
body weight through 52 weeks of treatment. Patients switching to exenatide QW experienced
further improvements in A1C and FPG, with sustained weight loss.
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T
ype 2 diabetes is a complex and in-
creasingly prevalent disease associ-
ated with interrelated comorbidities,
including obesity, dyslipidemia, and hy-
pertension. The importance of treating
not only hyperglycemia, but also the as-
sociated comorbidities, is recognized as
necessary to reduce the risk of complica-
tions, particularly cardiovascular disease
(1). Lifestyle modiﬁcation can improve
glycemic control as well as body weight,
blood pressure, and lipid proﬁles; how-
ever, behavioral modiﬁcations are inher-
ently difﬁcult, and most patients
eventually require multiple medications
(2–6). Although several classes of antihy-
perglycemicmedicationsarecurrentlyin-
dicated for the treatment of type 2
diabetes, most of them do not improve
the comorbidities and several are associ-
ated with weight gain.
Exenatide, a glucagon-like peptide-1
receptor (GLP-1R) agonist, improves gly-
cemic control in patients with type 2 dia-
betes through multiple mechanisms of
action: increased glucose-dependent in-
sulin secretion, attenuated postprandial
glucagonsecretion,slowedgastricempty-
ing, and increased satiety (7,8). The
twice-daily formulation of exenatide (ex-
enatide BID) improves both fasting and
postprandial glucose control, resulting in
A1C reductions of roughly 0.8–1.0% in
placebo-controlledtrials(9–12)and1.0–
1.4% in open-label trials (13–15). These
improvements in glucose control were
maintainedinpatientscompleting3years
of treatment (1.0%) (16). Exenatide
therapyisalsoassociatedwithweightloss
and improvement in cardiovascular risk
factors, including blood pressure and se-
rum lipid proﬁles (16). Furthermore, the
glucose-dependent mechanisms of action
of exenatide minimize the risk of hypo-
glycemia. GLP-1R agonists have recently
been added to the American Diabetes As-
sociation and European Association for
the Study of Diabetes consensus algo-
rithm for the treatment of type 2 diabetes
as an option after the addition of met-
formin in patients in whom body weight
and hypoglycemia risk are concerns (1).
Exenatide BID is administered within
the 60-min period before the morning
andeveningmealsandprimarilyexertsits
pharmacodynamic effects on glucose
concentrations during the postprandial
period. A long-acting once-weekly for-
mulation of exenatide (exenatide QW)
has been developed. Weekly administra-
tionof2mgexenatideQWresultsinther-
apeutic plasma exenatide concentrations
within 2 weeks and steady-state plasma
exenatide concentrations within the ther-
apeutic target range 6–7 weeks after ini-
tiation of therapy (17,18).
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searching Changes in A1C, Weight and
Other Factors Through Intervention with
Exenatide Once Weekly (DURATION-1)
trialwasdesignedasatwo-stageprotocol.
We previously reported the ﬁrst stage, a
randomizedopen-labelcomparisonofex-
enatide QW to exenatide BID in patients
with type 2 diabetes over 30 weeks (17).
Both therapies improved glycemic con-
trol, and the improvement in A1C ob-
served with exenatide QW treatment was
signiﬁcantly greater than that observed
with exenatide BID (1.9 vs. 1.5%, re-
spectively). Similar improvements in
body weight, blood pressure, and fasting
lipidsweredemonstratedwithbothforms
of exenatide therapy. We now describe
52-week results from the second phase of
the DURATION-1 trial which examined
the safety and efﬁcacy of 1) switching
fromexenatideBIDtoexenatideQWafter
30 weeks of treatment and 2) continuing
exenatideQWtreatmentforanadditional
22 weeks (52 weeks total).
RESEARCH DESIGN AND
METHODS
Randomization and interventions
Patientswererandomlyassignedtooneof
two open-label treatment groups: weekly
subcutaneous injections of 2 mg ex-
enatideQWor5gexenatideBIDforthe
ﬁrst 28 days followed by a required dose
increaseto10gBIDfortheremainderof
the 30-week assessment period. The in-
clusion and exclusion criteria and results
from the initial 30 weeks have been re-
ported previously (17). At 30 weeks, par-
ticipants entered a second, open-ended
treatment period in which all patients re-
ceived exenatide QW. Patients who
switchedfromexenatideBIDtoexenatide
QW treatment and were concomitantly
using a sulfonylurea (SFU) were required
to reduce their SFU dose to the minimum
recommended dose until week 40. Sub-
sequently, the SFU dose was up-titrated
based on daily glucose measurements to
reach a target fasting plasma glucose
(FPG) of 110 mg/dl. Patients originally
randomly assigned to exenatide QW
maintained their treatment regimen.
A common clinical protocol was ap-
proved for each site by the appropriate
institutional review board. Patients pro-
vided written informed consent before
participation. The study was conducted
in accordance with the principles de-
scribed in the Declaration of Helsinki, in-
cluding all amendments through the
South Africa revision (19).
Outcomes
For this second phase of the study, glu-
cose control during the transition from
exenatide BID to exenatide QW was ex-
amined, as well as the safety, tolerability,
andefﬁcacyof52weeksofexenatideQW
treatment. Plasma analytes and A1C were
quantitated by Quintiles Laboratories
(Smyrna, GA) using standard methods.
A1C was measured using high-perfor-
mance liquid chromatography. Plasma
antibodiestoexenatideweremeasuredby
Millipore Corporation Drug Discovery
(St. Charles, MO) using an enzyme-
linked immunosorbent assay (20). Titers
of antibodies to exenatide were deter-
mined by serial 1:5 dilutions after an ini-
tial dilution of 1:25 (also expressed as the
reciprocal of the highest dilution of sam-
ple serum that tests positive in the assay).
Blood pressure was measured after 5
min of quiet rest in a sitting position, re-
peatedafteratleast30s,andthetwomea-
surements were averaged.
Statistical analysis
Theintent-to-treat(ITT)populationcom-
prisedallrandomlyassignedpatientswho
receivedatleastoneinjectionofexenatide
in the previously reported phase of this
study (17). The 52-week evaluable popu-
lation consisted of ITT patients who com-
pleted the study visits to at least week 48
incompliancewiththeprotocol.Descrip-
tive statistics on demographics, analysis
of primary glycemic end points, body
weight, and fasting lipid concentrations
are provided for the 52-week evaluable
population. All safety analyses, including
blood pressure measurements, are pro-
vided for the ITT population. The analy-
ses of A1C were based on a general linear
model (ANOVA) including original treat-
ment assignment, baseline A1C stratum,
and concomitant SFU use at screening.
Baseline FPG, body weight, and blood
pressure were added in the model
(ANCOVA) for FPG, body weight, and
blood pressure, respectively. Data for
these efﬁcacy end points are expressed as
least squares means. There were no sub-
stantial differences in A1C (Fig. 2B)o r
other measures (data not shown) when
the evaluable population, the 52-week
ITT population, or those who partici-
pated after 30 weeks were examined.
Therefore, only data for the evaluable
population were reported. Statistical
analysis was performed using SAS (ver-
sion 8.2; SAS Institute, Cary, NC).
Treatment-emergent adverse events
weredeﬁnedasthoseoccurringduringor
aftertheﬁrstinjectionofexenatideQWin
theopen-endedassessmentperiod.Treat-
ment-emergent adverse events during the
initial 30 weeks of the trial were reported
previously (17). Hypoglycemia was cate-
gorized as major if the event 1)i nt h e
judgmentoftheinvestigatororphysician,
resulted in a loss of consciousness, sei-
zure, or coma and resolved after adminis-
tration of glucagon or glucose or 2)
required third-party assistance to resolve
and the subject had a glucose value of
54 mg/dl. Minor hypoglycemia was de-
ﬁned as a report of symptoms consistent
with hypoglycemia and a glucose value of
54 mg/dl before treatment of the
episode.
RESULTS
Patient disposition and baseline
characteristics
Of the 295 ITT patients, 258 patients
(87%)continuedintothesecondphaseof
thetrial(Fig.1).Demographicsandback-
ground therapy were similar between the
two 52-week evaluable cohorts. Overall,
243patientscompleted52weeksoftreat-
ment, representing 82% of the original
ITT population and 94% of the popula-
tion entering the second predeﬁned treat-
ment period.
Efﬁcacy of exenatide QW
During this 22-week assessment period,
patients who continued exenatide QW
treatment maintained improvements in
A1C (Fig. 2A), with a least squares mean
(95% CI) change from baseline A1C of
2.1% (2.2 to 1.9%) at week 30 and
2.0%(2.1to1.8%)atweek52.The
time course and durability of A1C im-
provements were similar for the ITT pop-
ulation and 52-week evaluable
population (Fig. 2B). Patients who
switchedfromexenatideBIDtoexenatide
QW (week 30 A1C reduction 1.8%
[1.9 to 1.6%]) exhibited further im-
provements in glycemic control such that
they achieved the same A1C reduction
(2.0%) and mean A1C (6.6%) at week
52 as patients receiving only exenatide
QW. After 52 weeks of treatment, 71% of
all patients achieved A1C 7.0% and
54% achieved A1C 6.5% (similar be-
tween cohorts) (Fig. 2D). In patients with a
baseline A1C 9.0% (baseline A1C 7.8%),
A1C reduction at week 52 was 1.2%
Exenatide once weekly, 52-week safety and efﬁcacy
1256 DIABETES CARE, VOLUME 33, NUMBER 6, JUNE 2010 care.diabetesjournals.orgFigure 1—Enrollment, patient disposition, and baseline characteristics. Of the 303 patients originally randomized to the study, 258 entered the
subsequent22-weekassessmentperiod.Fifteenpatientswithdrewduringthe22-weekassessmentperiod,resultinginanevaluablepopulationofn
241(n120QWonly;n121BID3QW).DemographicsoftheITTpopulationareavailableinDruckeretal.(17)andrepresenttheinformation
at the original baseline. MET, metformin; SFU, sulfonylurea; TZD, thiazolidinedione.
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1.2%) in the exenatide QW-only and
exenatide BID3exenatide QW groups,
respectively (supplementary Fig. 1, avail-
able in an online appendix at http://care.
diabetesjournals.org/cgi/content/full/dc09-
1914/DC1). Larger reductions in A1C at
week 52 were achieved in patients with a
baseline A1C 9.0%: 2.8% (3.1 to
2.5%) for the exenatide QW-only
group (baseline A1C 9.7%) and 2.6%
(3.0 to 2.3%) in the exenatide
BID3exenatide QW group (baseline
A1C 9.6%).
Body weight decreased similarly in
both treatment groups. At week 52, the
least squares mean (95% CI) changes in
bodyweightwere4.1kg(5.3to2.9
kg)and4.5kg(5.7to3.3kg)inthe
exenatide QW-only and exenatide
BID3exenatide QW groups, respectively
(Fig. 2E). The distribution of the change
in A1C with respect to changes in body
weight is shown in Fig. 2F. Ninety-seven
percent of all patients achieved reduc-
tions in A1C over 52 weeks (similar be-
tween cohorts) and most patients (77
and 79% of exenatide QW-only and ex-
enatide BID3exenatide QW, respec-
tively) achieved reductions in both A1C
and body weight. Signiﬁcant A1C re-
ductions were observed in both treat-
ment groups regardless of weight loss
Figure2—Glycemiccontrolandbodyweightover52weeks.A:LeastsquaresmeanSEchangesinA1Cover52weeksfortheevaluablepopulation
(exenatideQW-onlyn120;exenatideBID3exenatideQWn121).B:LeastsquaresmeanSEchangeinA1CforITT(n148)andevaluable
population patients receiving only exenatide QW for 52 weeks. C: Change in fasting plasma glucose over 52 weeks for the evaluable population. D:
Proportion of patients achieving A1C targets of 7.0, 6.5, and 6.0%. E: Least squares mean  SE changes in body weight over 52 weeks for the
evaluable population. F: Scatterplot of change in A1C vs. change in body weight. *P  0.05 versus exenatide BID3exenatide QW. BL, baseline.
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Glucose control during transition
from exenatide BID to exenatide QW
In patients who received exenatide QW
for 52 weeks, least squares mean (95%
CI) reductions in FPG at week 30 (46
mg/dl [52 to 40 mg/dl]) were main-
tained through week 52 (47 mg/dl
[53 to 41 mg/dl]) (Fig. 2C). Patients
who switched from exenatide BID to ex-
enatide QW achieved a similar reduction
in FPG at week 52 (43 mg/dl [49 to
37 mg/dl]) (Fig. 2C) relative to patients
who received exenatide QW for 52
weeks. Subsequent to week 30, BID-
treated patients who switched to ex-
enatide QW experienced a transient rise
in mean FPG concentration followed by a
rapid decrease within 2 weeks of the
switch (Fig. 2C). By 3–4 weeks after ini-
tiationofQWtreatment,themeanFPGin
thisgroupofsubjectshadreturnedtolev-
els observed before they switched to ex-
enatide QW, which was followed by
further improvements such that ulti-
mately the two groups exhibited similar
reductions in FPG. Patients concomi-
tantly taking an SFU (n  44) reduced
their SFU dose to the minimum recom-
mended dose at week 30 according to
protocol and experienced a greater rise in
FPG during the transition than patients
not taking an SFU (data not shown). At
week 52, 45% (n  20) of these patients
receivedalowerSFUdosecomparedwith
their SFU dose immediately before
switchingtoexenatideQW,whereas43%
(n  19) received the same SFU dose and
9% (n  4) increased the SFU dose at
week 52 compared with week 30. One
patient discontinued SFU treatment after
switching to exenatide QW.
Effects on blood pressure and fasting
lipids
Clinically signiﬁcant blood pressure im-
provements were observed in patients
treated with exenatide QW for 52 weeks
(least squares mean [95% CI] from base-
line: systolic blood pressure [SBP] 6.2
mmHg [95% CI 8.5 to 3.9 mmHg],
and diastolic blood pressure [DBP] 2.8
mmHg [4.3 to 1.3 mmHg]) and in
patients switching from exenatide BID to
exenatide QW (SBP 3.8 mmHg [6.1
to 1.5 mmHg] and DBP 1.8 mmHg
[3.2 to 0.3 mmHg]) (Fig. 3A). Fifty
and 46% of patients (exenatide QW and
exenatide BID3exenatide QW, respec-
tively) with elevated SBP (130 mmHg)
at baseline achieved normal SBP at week
52. Changes in concomitant antihyper-
tensive medications were only allowed if
deemed necessary by the investigator.
The majority (84%) of the 154 subjects
who had been using an antihypertensive
medication at screening and completed
52 weeks of treatment did not change
their dose. Of patients who did change
theirdose,9patientsincreasedtheirdose,
13 patients decreased their dose, and 1
patient stopped the medication. In addi-
tion, 14 patients initiated antihyperten-
sive medication after screening.
Improvements in serum lipid proﬁles
were demonstrated in both treatment
groups, with clinically signiﬁcant reduc-
tions in total cholesterol (9.6 mg/dl
[14.8 to 4.3 mg/dl] and 9.0 mg/dl
[14.5 to 3.6 mg/dl]) (Fig. 3B) and
triglycerides (15% [21 to 9%].
Safety and tolerability
Treatment-emergentadverseeventsthatoc-
curredfortheﬁrsttimeorworsenedduring
this second phase of DURATION-1 were
similar to those observed during the 30-
week assessment period (Table 1) (17).
Nausea was predominantly mild in inten-
sity. No severe nausea was reported.
Twenty-one patients (8%; n  4 for ex-
enatide QW-only and n  17 exenatide
BID3exenatide QW) reported injection-
site related adverse events including
bruising, erythema, hemorrhage, indura-
tion,pain,andpruritus.Mildtomoderate
injection site pruritus was observed after
switching from exenatide BID to ex-
enatide QW in six patients (ﬁve of these
patients did not experience pruritus dur-
ing the initial 30-week assessment). No
injection site–related adverse events led
to withdrawal. There were no episodes of
Figure3—Changefrombaselineinbloodpressureandserumlipids.A:Patients(ITTpopulation)
inbothtreatmentgroupsexhibitedfavorablechanges(leastsquaresmeanchangefrombaseline
SE)inbloodpressureafter52weeksoftreatment.B:TreatmentwithexenatideQWwasassociated
withfavorablechangesinserumlipids(evaluablepopulation).Dataarepresentedasleastsquares
mean  SE for all lipids except for triglycerides (geometric least squares mean milligrams per
deciliter baseline; geometric least squares mean percent change  SE from baseline). ITT popu-
lation: exenatide QW-only n  148; exenatide BID3exenatide QW n  147. Evaluable popula-
tion: exenatide QW-only n  120; exenatide BID3exenatide QW n  121. BL, baseline.
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nor hypoglycemia was low and was lim-
ited to patients using a concomitant SFU
during weeks 30–52 (9% of patients re-
ceiving an SFU) (supplementary Table 1,
available in an online appendix). Anti-
bodiestoexenatidetiterpeakedatweek6
for both treatment groups (geometric
mean  SE 33.2  8.2 and 12.6  3.4
for exenatide QW-only and exenatide
BID3exenatide QW groups, respec-
tively). At week 52, antibody titers to ex-
enatidewere12.83.4and8.92.1for
exenatide QW-only and exenatide
BID3exenatide QW groups, respectively
(supplementary Table 2, available in an
online appendix). Antibodies to ex-
enatide were not predictive of individual
A1C change or incidence of treatment-
emergent adverse events. One patient
withdrew because of an adverse event
(worsening of type 2 diabetes) during the
22-week assessment period (exenatide
QW-only group). No cases of pancreatitis
were reported.
CONCLUSIONS — The improve-
ments in glycemic control and body
weight observed after 30 weeks of ex-
enatide QW treatment (17) were sus-
tained in patients continuing exenatide
QW treatment for 52 weeks. Patients
switching from exenatide BID to ex-
enatide QW exhibited further improve-
ments in glycemic control. Similar
improvements in glycemic control, body
weight, and cardiovascular risk factors
were observed at week 52 regardless of
initial randomized treatment. Although
the absence of a comparator arm is a lim-
itation of this study and the open-label
trial design inherently offers the potential
for bias and can affect patient expecta-
tions, the results of this study demon-
strated reductions in A1C and body
weight comparable to those in a previ-
ously reported double-blind, placebo-
controlled study of exenatide QW at the
same dose (18) and were consistent with
continuous exenatide exposure. These
improvements were greater than those
previously observed with exenatide BID
in both placebo-controlled (9–12) and
open-labelcomparatortrials(13–15).Itis
important to note that improvements in
A1C were observed across the spectrum
of baseline A1C values and weight loss
categories.TreatmentwithexenatideQW
was generally well tolerated and treat-
ment-emergent adverse events were
generally mild to moderate. As in the
initial 30-week phase, the only inci-
dences of mild to moderate hypoglyce-
mia occurred in patients concomitantly
receiving an SFU.
It is noteworthy that patients switch-
ing from exenatide BID to exenatide QW
experienced a transient elevation in FPG,
whichgenerallyimprovedwithin2weeks
after initiation of QW therapy. This tran-
sient rise in FPG can be largely attributed
to the time required for plasma exenatide
levels to reach the therapeutic range after
initiation of exenatide QW and was of a
magnitude(15mg/dl)thatisunlikelyto
be associated with symptoms or harm
over a short period of time. In addition,
subjects who switched treatment and
were using a concomitant SFU were re-
quired to reduce their SFU dose to the
minimum recommended dose for initia-
tion of exenatide QW treatment. There-
fore, the transient rise in FPG
concentration may also reﬂect SFU dose
adjustments. It is important to note that
the highest point in the transient FPG rise
represented a mean decrease of 16
mg/dl from baseline. There was no clini-
cally signiﬁcant effect on overall glycemic
control after the switch to exenatide QW
(mean rise in mean A1C was 0.1%).
A1C values subsequently declined below
those observed with 30 weeks of ex-
enatide BID treatment and by week 44
matched those observed with continuous
exenatide QW treatment. Overall, these
ﬁndings suggest that switching from ex-
enatide BID to QW, although associated
with a transient increase in glycemia, ul-
timately leads to signiﬁcantly improved
glycemic control.
Achieving glycemic targets remains
an elusive goal for many patients with
type 2 diabetes. Furthermore, improving
weight and cardiovascular risk markers
and avoiding hypoglycemia are desired
components of a diabetes treatment pro-
gram. GLP-1R agonists were recently rec-
ommended as second-step treatment
option in patients in whom avoidance of
hypoglycemia or promotion of weight
loss is a major concern (1). In the present
study, the transition from exenatide BID
to exenatide QW was made without addi-
tional safety and tolerability concerns.
Furthermore, the clinical beneﬁts of ex-
enatide QW were maintained and re-
sulted in a mean A1C of 6.6% after 52
weeks of treatment.
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Table 1—Treatment-emergent adverse events >5% incidence during open-ended assessment
period (week 30 through week 52)
Preferred term
Exenatide QW
(n  128)
Exenatide BID3Exenatide QW
(n  130)
Upper respiratory tract infection 12.5 12.3
Diarrhea 8.6 6.9
Nausea 7.0 7.7
Nasopharyngitis 7.8 4.6
Sinusitis 4.7 6.9
Vomiting 6.3 4.6
Urinary tract infection 2.3 5.4
Injection site bruising 0 5.4
Data are % unless otherwise indicated. Adverse events that occurred for the ﬁrst time or existed before week
30 and worsened after the ﬁrst injection at week 30 through study termination are reported.
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